AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Iovance Biotherapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001T2PM32
14.09▼ 0.05 (-0.35%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
14.14
Day's Range
13.54 – 14.30
52-Week Range
1.76 – 15.37
Volume
7.7M
Avg Volume
16.2M
Share Statistics
Shares Outstanding
Employees
975
Exchange
XNAS
Listed
2010-05-26
Share count as of July 29, 2026

Iovance Biotherapeutics, Inc. Common Stock (IOVA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Iovance Biotherapeutics, Inc. Common Stock (IOVA)
What is Iovance Biotherapeutics, Inc. Common Stock's Market Cap?
Iovance Biotherapeutics, Inc. Common Stock's Market Cap is $6.4B, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's Enterprise Value?
Iovance Biotherapeutics, Inc. Common Stock's Enterprise Value is $6.1B, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's Price / Sales?
Iovance Biotherapeutics, Inc. Common Stock's Price / Sales is 19.6×, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's EV / Revenue?
Iovance Biotherapeutics, Inc. Common Stock's EV / Revenue is 18.7×, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's EV / EBITDA?
Iovance Biotherapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's Revenue (TTM)?
Iovance Biotherapeutics, Inc. Common Stock's Revenue (TTM) is $325.0M, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's Net Income (TTM)?
Iovance Biotherapeutics, Inc. Common Stock's Net Income (TTM) is -$289.5M, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's EBITDA?
Iovance Biotherapeutics, Inc. Common Stock's EBITDA is -$287.8M, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Iovance Biotherapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.64, based on as-reported figures from SEC (XBRL) filings.
What is Iovance Biotherapeutics, Inc. Common Stock's EBITDA Margin?
Iovance Biotherapeutics, Inc. Common Stock's EBITDA Margin is -88.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IOVAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations
Total revenue
YoY growth+65.7%+44.8%+17.7%+15.2%
Costs and expenses
Cost of sales
Research and development
Selling, general, and administrative
Depreciation and amortization
Total costs and expenses
% of revenue152.3%213.5%184.7%240.7%
Loss from operations
% of revenue-52.3%-113.5%-84.7%-140.7%
Other income
Interest and other income, net
Net Loss before income taxes
Net Loss
% of revenue-47.6%-110.7%-82.9%-135.3%
Net Loss Per Share of Common Stock, Basic (in dollars per share)—
Net Loss Per Share of Common Stock, Diluted (in dollars per share)——